Digest Network Come funziona
Network
/
Società
La
Non verificato

Laminar Pharmaceuticals, S.A.

Di cosa scriviamo

BiologiaEcologia/Salute ambientaleFarmaceuticaFitnessSanità

3 comunicati stampa

Guarda tutti i comunicati
Press Release cover image
24/07/2026
Salute
Fitness
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
Fonte
Laminar Pharmaceuticals, S.A.
Emittente
PR News Wire
1.00
0
05/03/2025
Farmaceutica
Sanità
Biologia
Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients
Fonte
Laminar Pharmaceuticals, S.A.
Emittente
PR News Wire
1.00
0
Press Release cover image
11/06/2024
Farmaceutica
Sanità
Last patient in: Laminar Pharmaceuticals S.A. completes recruitment for CLINGLIO, the phase 2b/3 Clinical Trial of idroxioleic acid (LAM561) in combination with RT and TMZ for adults with newly diagnosed glioblastoma
Fonte
Laminar Pharmaceuticals, S.A.
Emittente
PR News Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0